Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sabrina Huffman

Nurse Practitioner, Family Princeton, WV Nurse Practitioner

NPI 1366720047 CMS profile 10497204

3997 Beckley Rd, Princeton, WV 24740

Open in the dashboard

General payments

$6,867

439 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sabrina Huffman of Princeton, WV is reported in the CMS Open Payments database as having received $6,867 across 439 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $905 59
2024 General $1,404 91
2023 General $1,574 89
2022 General $1,270 85
2021 General $1,714 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sabrina Huffman
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Sabrina Huffman were reported at $905. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Sabrina Huffman Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,714 $124 $35–$379 $132
2022 $1,270 $141 $44–$430 $149
2023 $1,574 $154 $49–$476 $160
2024 $1,404 $165 $51–$504 $164
2025 $905 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,169 79 payments
  2. Lilly USA, LLC $843 57 payments
  3. AbbVie, Inc. $817 62 payments
  4. AstraZeneca Pharmaceuticals LP $588 30 payments
  5. GlaxoSmithKline, LLC. $577 44 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $538 28 payments
  7. Abbott Laboratories $383 21 payments
  8. Merck Sharp & Dohme Corporation $292 21 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $247 15 payments
  10. Exact Sciences Corporation $225 11 payments
  11. Other $1,188 71 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,867 439 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,047 68 payments
  2. RYBELSUS $974 63 payments
  3. FARXIGA $543 27 payments
  4. JARDIANCE $457 29 payments
  5. TRELEGY ELLIPTA $389 31 payments
  6. OFEV $382 17 payments
  7. FreeStyle Libre 2 $352 19 payments
  8. MOUNJARO $335 25 payments
  9. ZEPBOUND $252 15 payments
  10. Kerendia $247 15 payments
  11. Other $4,925 320 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 116 drugs

Part D claims

5,704

Median for Nurse Practitioner: 389

Drug cost

$418,789

Median for Nurse Practitioner: $21,885

Branded share of claims

16.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 59 $74,248
Farxiga Dapagliflozin Propanediol Brand 31 $43,639
Mounjaro Tirzepatide Brand 40 $43,457
Jardiance Empagliflozin Brand 47 $41,369
Januvia Sitagliptin Phosphate Brand 42 $40,122
Tresiba Flextouch U-100 Insulin Degludec Brand 29 $25,224
Eliquis Apixaban Brand 26 $21,751
Linzess Linaclotide Brand 17 $18,360
Kerendia Finerenone Brand 18 $17,147
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 11 $16,340

The 10 drugs with the highest cost, of 116 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $202
$202 — —
RYBELSUS
  • Novo Nordisk Inc $109
$109 — —
Ozempic
  • Novo Nordisk Inc $98
$98 59 —
MOUNJARO
  • Lilly USA, LLC $94
$94 40 —
VRAYLAR
  • AbbVie, Inc. $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

439 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record